Neurizon Therapeutics (ASX:NUZ) Tax Rate %: 66.70% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neurizon Therapeutics Tax Rate %?

Neurizon Therapeutics ASX:NUZ -1.25% Tax Rate % is 66.70% as of Jun. 2026. The stock has 2 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Neurizon Therapeutics's Tax Expense for the six months ended in Jun. 2026 was A$-10.39 Mil. Neurizon Therapeutics's Pre-Tax Income for the six months ended in Jun. 2026 was A$-15.57 Mil. Therefore, Neurizon Therapeutics's Tax Rate % for the quarter that ended in Jun. 2026 was 66.70%.

Neurizon Therapeutics Tax Rate % Related Terms

Neurizon Therapeutics Tax Rate % Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Tax Rate % Chart

Neurizon Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 29.38 5.85 8.48 60.41

Neurizon Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 17.38 0.07 51.89 66.70

Neurizon Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Neurizon Therapeutics's Tax Rate % for the fiscal year that ended in Jun. 2026 is calculated as

Tax Rate %=Tax Expense (A: Jun. 2026 )/Pre-Tax Income (A: Jun. 2026 )
=-16.36069/-27.083714
=60.41 %

Neurizon Therapeutics's Tax Rate % for the quarter that ended in Jun. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Jun. 2026 )/Pre-Tax Income (Q: Jun. 2026 )
=-10.387589/-15.573277
=66.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 66.70% mean?
Neurizon Therapeutics (ASX:NUZ) has a Tax Rate % of 66.70% as of Jun. 2026.
Is Neurizon Therapeutics' Tax Rate % too high?
Neurizon Therapeutics' current Tax Rate % is 66.70%.
How does Neurizon Therapeutics' Tax Rate % compare to VRTX and REGN?
Neurizon Therapeutics' Tax Rate % of 66.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Neurizon Therapeutics's current Tax Rate % is 66.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (ASX:NUZ) has a current Tax Rate % of 66.70%. The current Tax Rate % is 66.70%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Neurizon Therapeutics (ASX:NUZ), the current Tax Rate % is 66.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:Germany
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Neurizon Therapeutics Ltd is an Australian clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead candidate, NUZ-001 (S-monepantel), is being developed as a potential therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions, based on the drug's proposed neuroprotective and anti-inflammatory mechanisms. The company's pipeline centers on repurposing and reformulating existing molecules for neurological indications, with an emphasis on progressing NUZ-001 through clinical trials. As a clinical-stage company, Neurizon does not yet generate product revenue; its funding comes primarily from equity capital raised from investors, along with any research grants or collaborations. Its activities span preclinical research, clinical development, and regulatory interactions, with operations based in Australia and a target market encompassing global patients with neurodegenerative disorders.